Mirati Therapeutics (MRTX) Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRTX shares.
View MRTX analyst ratings or view top-rated stocks.

12 Wall Street research analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $40.00 to $188.00. On average, they predict the company's share price to reach $76.93 in the next year. This suggests a possible upside of 101.1% from the stock's current price.
View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts.

Mirati Therapeutics' stock was trading at $45.31 at the start of the year. Since then, MRTX shares have decreased by 15.6% and is now trading at $38.26.
View the best growth stocks for 2023 here.

Mirati Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 6,760,000 shares, a decrease of 14.8% from the April 30th total of 7,930,000 shares. Based on an average daily trading volume, of 981,200 shares, the short-interest ratio is presently 6.9 days.
View Mirati Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MRTX earnings forecast.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings results on Tuesday, May, 9th. The biotechnology company reported ($3.18) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.29. The biotechnology company earned $7.17 million during the quarter, compared to the consensus estimate of $4.80 million. Mirati Therapeutics had a negative net margin of 3,901.06% and a negative trailing twelve-month return on equity of 71.90%. Mirati Therapeutics's revenue was up 910.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.40) EPS.

ETFs with the largest weight of Mirati Therapeutics (NASDAQ:MRTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED) and iShares Biotechnology ETF (IBB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.35%), BlackRock Inc. (5.57%), Wellington Management Group LLP (4.64%), State Street Corp (3.97%), Price T Rowe Associates Inc. MD (3.04%) and Perceptive Advisors LLC (2.71%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Laurie Stelzer, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends.

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRTX stock can currently be purchased for approximately $38.26.

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.23 billion and generates $18.89 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.96) on an earnings per share basis.

The company employs 413 workers across the globe.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.